Triple

T22717591
Position Surface form Disambiguated ID Type / Status
Subject Genzyme E561775 entity
Predicate hasProduct P3585 FINISHED
Object Myozyme
Myozyme is an enzyme replacement therapy used to treat Pompe disease, a rare genetic disorder caused by acid alpha-glucosidase deficiency.
 E1550579 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Myozyme | Statement: [Genzyme, hasProduct, Myozyme]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Myozyme
Context triple: [Genzyme, hasProduct, Myozyme]
  • A. Fabrazyme
    Fabrazyme is a biologic enzyme replacement therapy used to treat Fabry disease by supplementing the deficient alpha-galactosidase A enzyme.
  • B. Cerezyme
    Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
  • C. Lumizyme
    Lumizyme is an enzyme replacement therapy used to treat patients with Pompe disease by supplementing deficient acid alpha-glucosidase.
  • D. Genzyme
    Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
  • E. Strensiq
    Strensiq is a prescription enzyme replacement therapy used to treat patients with perinatal-, infantile- and juvenile-onset hypophosphatasia, a rare genetic bone disorder.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Myozyme
Triple: [Genzyme, hasProduct, Myozyme]
Generated description
Myozyme is an enzyme replacement therapy used to treat Pompe disease, a rare genetic disorder caused by acid alpha-glucosidase deficiency.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Myozyme
Target entity description: Myozyme is an enzyme replacement therapy used to treat Pompe disease, a rare genetic disorder caused by acid alpha-glucosidase deficiency.
  • A. Fabrazyme
    Fabrazyme is a biologic enzyme replacement therapy used to treat Fabry disease by supplementing the deficient alpha-galactosidase A enzyme.
  • B. Cerezyme
    Cerezyme is a biologic enzyme replacement therapy used to treat patients with Gaucher disease type 1 by supplementing the deficient glucocerebrosidase enzyme.
  • C. Lumizyme chosen
    Lumizyme is an enzyme replacement therapy used to treat patients with Pompe disease by supplementing deficient acid alpha-glucosidase.
  • D. Genzyme
    Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
  • E. Strensiq
    Strensiq is a prescription enzyme replacement therapy used to treat patients with perinatal-, infantile- and juvenile-onset hypophosphatasia, a rare genetic bone disorder.
  • F. None of above.

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454fc984819088213b58ee87a002 completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1790ecbc48190926d16b20b674dbd completed April 29, 2026, 3:20 a.m.
NED1 Entity disambiguation (via context triple) batch_6a0b980ad26c8190b89fa1649dd80675 completed May 18, 2026, 10:51 p.m.
NEDg Description generation batch_6a0b98d159688190a5ec037ee8692f33 completed May 18, 2026, 10:55 p.m.
NED2 Entity disambiguation (via description) batch_6a0b99b6e7e88190995319351374f97c completed May 18, 2026, 10:59 p.m.
Created at: April 17, 2026, 3:19 p.m.